Introduction {#S1}
============

Trillions of microbes inhabit the human body, collectively forming the human microbiota. These microbes create complex, organ-specific and adaptive ecosystems, which continually impact the host's physiology. The microbiota and its overall genetic material (the microbiome) consist of bacteria (bacteriome), archaea (archeome), fungi (mycobiome), viruses (virome), and parasites (parasitome). Together they play a pivotal part in human and animal physiology through influencing digestion, immune development, vitamin production, and likely behavior and mental wellbeing ([@B8]; [@B9]; [@B12]; [@B38]). Beneficial effects of certain microorganisms are reflected in the concept of probiotics, defined as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host" ([@B30]). Also, certain microbial substrates, called prebiotics, can be selectively utilized by host microorganisms, thereby conferring a health benefit ([@B23]). Thus, by supplementing with appropriate probiotics and/or prebiotics, it is possible to provide added benefits to human health.

The fields of probiotics, prebiotics, and related microbiome research have seen remarkable advances in the last decades ([@B62]). Novel tools offer alternatives to traditional *in vitro* and *in vivo* models ([Table 1](#T1){ref-type="table"}), allowing more efficient generation of convincing data on the probiotic and prebiotic mode of action, their effect on the microbiome, and the resulting clinical health outcomes. Numerous clinical trials provide evidence of strain-specific probiotic and prebiotic benefits for a range of health conditions, including diarrhea ([@B27]) vaginal dysbiosis ([@B54]), respiratory infections ([@B29]), bowel function ([@B76]) body weight ([@B49]) and bone mineralization ([@B1]). These findings have sparked an interest from the press and general public, emphasizing the need for correct and accessible scientific communication around these topics. Taken together, this calls for a discussion on the research possibilities and implementation of probiotics and prebiotics and their interaction with the host microbiome ([Figure 1](#F1){ref-type="fig"}).

###### 

Promising in *vitro, in vivo*, and *in silico* techniques for probiotics and prebiotics research.

  Technique                                                             Use                                                                                                                                               Advantages                                                                                                                                                                                                                                       Limitations                                                                                                                                                                                                                        References
  --------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  **Microbiome and *in silico* methods and models**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Full shotgun metagenomics sequencing                                  To sequence the genomes of untargeted cells in a community to elucidate community composition and function                                        Untargeted, allows simultaneous detection of bacterial, fungal and viral sequences, greater taxonomy resolution and functional profiling                                                                                                         Expensive, requires more extensive data analysis due to host DNA interference                                                                                                                                                      [@B35]
  Strain-specific quantitative polymerase chain reaction (qPCR)         To quantify target DNA sequences for specific probiotic strains                                                                                   Faster high-throughput detection and quantification of target DNA sequences, high sensitivity enables quantification of microorganisms with low abundance on strain level within an environmental sample                                         Design of primers that specifically target strains of interest despite the presence of closely related strains is not trivial, requires adequate validation, results need to be correlated with phenotypic and biochemical tests   [@B72], [@B40]
  KatharoSeq                                                            High-Throughput Microbiome Analysis of Low-Biomass Samples                                                                                        Able to differentiate a true positive signal in samples with as few as 50 bacterial cells, high-throughput, single tube DNA extractions, automated, incorporates positive and negative controls, combines laboratory and bioinformatic methods   Careful selection of positive controls necessary                                                                                                                                                                                   [@B44]
  RIDE checklist                                                        Minimum standards checklist for low microbial biomass microbiome studies                                                                          Improves the validity of low microbial biomass research by reporting methodology, including controls, determining level of contamination and exploring impacts of contamination in downstream analysis                                           Sample collection recommendations difficult to implement in some clinical settings                                                                                                                                                 [@B20]
  **Metabolite/protein detection methods**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ^1^H-NMR-spectroscopy                                                 Detection of metabolites in biological samples                                                                                                    Not destructive, minimal sample preparation, broad                                                                                                                                                                                               Less sensitive than mass spectrometer-based methods, quantification of metabolites challenging                                                                                                                                     [@B6]
  Targeted Tandem Mass Spectrometry (TQ, QTrap)                         Targeted analysis of metabolites, hypothesis-driven research                                                                                      High sensitivity and specificity, absolute quantification                                                                                                                                                                                        Limited spectrum of metabolites, risk of false positives                                                                                                                                                                           [@B25], [@B63]
  Untargeted Tandem Mass Spectrometry (Q-TOF, LTQ-Orbitrap)             Global profiling of metabolites, hypothesis-generating research                                                                                   Comprehensive analysis, can detect unknown metabolites                                                                                                                                                                                           Relative quantification, libraries for annotating incomplete, risk of false negatives.                                                                                                                                             [@B25], [@B63]
  Proteomics                                                            Detection of expressed proteins                                                                                                                   Untargeted, direct method, high sensitivity, allows identification of human and bacterial proteins                                                                                                                                               Low throughput, time consuming, requires known peptide annotation, likelihood of 100% amino acid sequence identity between proteins produced by different species is low, same protein might be expressed by various organisms     [@B77]
  **Genetic manipulation**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  CRISPR-Cas9                                                           Targeted genetic manipulation                                                                                                                     Efficient and specific, limited off-target mutation, no need for a permanent antibiotic marker                                                                                                                                                   Often demands subsequent transformations, limited to genetic sites with a PAM motif present                                                                                                                                        [@B75], [@B74]
  Food-grade cloning vectors                                            Genetic manipulation of food-grade probiotics for safe use in humans and animals                                                                  To create genetically modified probiotics that meet the non-toxic and safe for consumption criteria (e.g., isogenic probiotic mutants for mechanistic studies in humans)                                                                         Limited functional marker genes                                                                                                                                                                                                    [@B33], [@B74]
  Genetic modification of probiotics to produce therapeutic molecules   Next-generation probiotics as delivery vehicles for bioactive compounds or antigens                                                               Combination of beneficial probiotic action with targeted delivery of therapeutic molecules aimed against specific diseases                                                                                                                       Approval for general use under current regulation is challenging, need for extensive safety testing and strict biocontainment strategies                                                                                           [@B32], [@B13]
  ***In vitro/ex vivo* techniques, tissue and organ models**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  RNAseq                                                                Measures gene transcription in bacterial communities and host, provides information about gene expression under different ecological conditions   Allows to determine transcriptional responses, not limited to genomic sequences, quantifiable                                                                                                                                                    Dependent on successful cDNA synthesis, challenging for short-lived transcripts                                                                                                                                                    [@B45]
  Explants and organotypic tissue models                                Assessment of safety, mechanisms of action and potential efficacy of probiotic candidate                                                          Three-dimensional tissue structures, differentiated cell composition, reflective of human physiology                                                                                                                                             Limited culture time and thus limited potential for long-term studies, not suitable for predicting systematic effects                                                                                                              [@B32], [@B47]
  Organoids                                                             Assessing probiotic efficacy and mechanisms of action at organ-level biological read-outs                                                         High reproducibility, recapitulation of 3D physiological structures                                                                                                                                                                              Variability in cell types/heterogeneity, less appropriate for studying effects on stratified tissues                                                                                                                               [@B28]
  Microfluidic organ-on-a-chip models                                   Kinetic assessment of prebiotic, probiotic and microbiota effects on host cells                                                                   Reflect the physiological complexity of dynamic niches, allow kinetic read-outs                                                                                                                                                                  Technologically challenging                                                                                                                                                                                                        [@B7], [@B26]
  Mini bioreactors                                                      Study metabolites and capture community changes                                                                                                   Traditional fermentation model, high throughput, reduced volume                                                                                                                                                                                  No precise pH control in place, no distinct compartments of the colon, no interactions with host cells                                                                                                                             [@B5]
  ***In vivo* approaches**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Humanized animal models                                               Evaluating microbe-host and prebiotic-host interactions                                                                                           Increased translational value compared to traditional animal models, more accurate modeling of specific human-like host responses, possibility to colonize animals with defined probiotic strains or human microbiota                            Not representative from a host-specific evolutionary perspective, technical challenges (e.g., graft rejections of human microbiota or immune cells), ethical concerns                                                              [@B42]
  Osmotic pill                                                          Real-time *in vivo* microbiome sampling along the gastrointestinal tract                                                                          Ingestible, biocompatible and battery-less with an osmotic sampler and microfluidic channels, allows real-time *in vivo* sampling along gut lumen                                                                                                Collection time is variable and influenced by individual peristaltic movement                                                                                                                                                      [@B48]
  Randomized controlled trials                                          Assessment of prebiotic and probiotic intervention outcomes under controlled conditions                                                           Gold standard to assess intervention outcomes in humans                                                                                                                                                                                          Expensive, time-consuming, randomization might prevent patient stratification based on relevant personal parameters, outcomes might be different in different patient populations                                                  [@B3], [@B61], [@B50]

![Key concepts for the development of the probiotics and prebiotics fields. We propose a systems approach linking research tools and clinical application to translate the potential health benefits observed during research into real-life outcomes. For example, not only the probiotics and prebiotics themselves should be considered, but also the real-time interactions with the host, microbial functionality, individual factors, and the regulation and safety aspects. Furthermore, various environmental and social needs can and should be addressed by probiotics and prebiotics.](fmicb-11-01400-g001){#F1}

Developments in Probiotics and Prebiotics Research {#S2}
==================================================

Considerations for Probiotics Research {#S2.SS1}
--------------------------------------

### Genetic Characterization and Modification of Probiotics {#S2.SS1.SSS1}

Bioinformatics and *in silico* approaches contribute to a more detailed understanding of beneficial microorganisms, thereby allowing their targeted usage and safety assessment. As whole genome sequencing (WGS) is available at a reasonable cost, we advise that qualitative WGS and rigorous annotation should become the standard practice prior to marketing new probiotic strains. Newly sequenced genomes should be deposited and made publicly available via standard central databases (e.g., GenBank^[1](#footnote1){ref-type="fn"}^, DDBJ^[2](#footnote2){ref-type="fn"}^, ENA^[3](#footnote3){ref-type="fn"}^). A rigorous sequence quality control and annotation should be carried out ([@B67]) identifying the mobile and other genetic elements (e.g., CRISPR arrays) and predicting their functional properties, thereby estimating the safety of probiotic candidates regarding virulence factors and possible antibiotic resistance gene transfer. The European Food Safety Authority (EFSA) and recent publications recommend WGS to improve the monitoring of foodborne antimicrobial resistance ([@B14]; [@B19]) and workflows to assess risk-related gene traits based on WGS are available ([@B60]). WGS is also useful to assess genetic instability and ensure the retention of regions linked to the strain's health benefits, as demonstrated for the *Lacticaseibacillus rhamnosus* GG variants with and without *spaCBA* pili genes ([@B69]).

Genetic manipulation is an important tool to study probiotic mechanisms of action \[e.g., by using isogenic mutant strains ([@B37])\] and to potentially create improved strains ([@B36]; [@B51]). However, a lack of sufficient genetic tools available for some probiotic species, especially food-grade systems for bifidobacteria, and a legal framework for the use of genetically manipulated/enhanced organisms limits the research progress ([@B2]; [@B4]). In addition to ethical and legal questions, it is not yet common practice to send genetic constructs to biological repositories. The considerable effort it takes to make these constructs and regulations within the research institutions are probably the main reasons to keep this genetic material in-house. We therefore advocate for a better sharing of genetic constructs by providing the material to the scientific community through existing repositories (e.g., AddGene, European Nucleotide Archive). This can save a substantial investment of time and research funds and will serve to enlarge the genetic tools box for probiotics. In particular, the development of safe vectors (e.g., food-grade vectors) is a necessary step in genetically tweaking probiotic strains for industrial and pharmaceutical applications ([@B33]), including specialized probiotics designed to deliver bioactive compounds to more effectively target specific diseases ([Table 1](#T1){ref-type="table"}). Both fundamental and applied probiotics research would benefit from a vast investment in genetic elements, and a better understanding of their mechanism of action and specificity ([@B2]). Genetic and bioinformatic training and experience in these interdisciplinary areas will thus be key for researchers making progress in the probiotics field.

### *In vitro* Models in Probiotics Research {#S2.SS1.SSS2}

Animal models are not strictly necessary for preclinical assessment of probiotics. While humanized animal models can be implemented ([Table 1](#T1){ref-type="table"}), it is highly challenging to develop ones that simulate microbe-host interaction in humans for niches demonstrating unique physiological features such as the lactobacilli-dominated vaginal niche characterized by a low pH ([@B43]). Human-based *in vitro* and *ex vivo* models followed by small studies with healthy volunteers and larger clinical intervention studies are invariably required to draw more precise and relevant conclusions on probiotic safety, action, and health benefits.

Recent cutting-edge *in vitro* and *ex vivo* approaches based on human cells and tissues pave the way beyond *in vitro* cell lines and animal models ([Table 1](#T1){ref-type="table"}). Reproducible human organoids have been used to recapitulate irritable bowel syndrome manifestations and the restorative effects of *L. rhamnosus* GG ([@B28]). Sophisticated organs-on-chips combine advances in human cell culturing with microelectronics and microfluidics to discover the anti-cancer potential of probiotic and synbiotic formulations, however, they are limited due to lack of exposure to host defenses ([@B7]; [@B26]). Cervico-vaginal tissue explants and organotypic tissue models circumvent this by combining human epithelial and immune cells and have previously allowed to identify anti-HIV-1 effects of wild type and genetically modified lactobacilli ([@B32]; [@B47]).

It is notable that on September 10, 2019, the United States Environmental Protection Agency released a memorandum stating that studies on mammals will be eliminated by 2035. This has implications for early career scientists developing their future line of research, opening opportunities for implementation of alternative *in vitro* models.

Considerations for Prebiotics Research {#S2.SS2}
--------------------------------------

### *In vitro* Methods to Study Prebiotics and Their Targets {#S2.SS2.SSS1}

Early prebiotic research was focused on the ability of compounds to stimulate bifidobacterial growth in the gut. Now, research has expanded to prebiotics targeting other species in the gut, but also in the vagina, lung, and skin ([@B23]; [@B15]). This offers opportunities for prebiotics beyond dietary non-digestible carbohydrates targeting colonic microbiota. Studies are warranted to identify novel prebiotics, especially by experts in chemistry and food science, and engineers designing delivery systems. In addition, synbiotics can exert a synergistic effect on host health with promising clinical effects against neonatal sepsis ([@B50]) and insulin resistance ([@B21]).

A diverse array of *in vitro*, *in vivo*, and *in silico*-based techniques has been applied to understand the mechanisms of action and efficacy of prebiotics ([Table 1](#T1){ref-type="table"}). The traditional method has been a bottom-up approach, where candidate prebiotics are screened by *in vitro* techniques, such as single strain culturing and chemostat fermentation of stool samples, before employing them in animal models and human intervention studies.

A novel top-down systems biology-based approach has recently been developed through *in silico* methods, which involve computer modeling and analysis of biological processes and interactions. For this, existing metagenomics and genomic data from human studies are mined to identify potential novel beneficial species able to prosper with the compound being tested. The prebiotics for these species are then selected by metabolic models based on microbial genomic data ([@B65]; [@B71]). Attempts have been made to create metabolic models of microbial inhabitants of the gut, to unravel the complex cross-feeding that occurs within the gut microbiota ([@B66]). We argue that *in silico* techniques are useful complements to classical techniques, and their implementation has the potential to improve the design of human studies.

### Importance of Metabolomics for Prebiotics {#S2.SS2.SSS2}

The recent expansion of the prebiotic concept to include other types of compounds in addition to non-digestible carbohydrates, such as polyphenols and certain fatty acids (e.g., polyunsaturated fatty acids), has resulted in greater emphasis on untargeted metabolome analysis ([@B10]). Microbial biotransformation of dietary phytochemicals (e.g., polyphenols) leads to a diverse array of metabolites, more bioavailable than the parent compound. These could enhance health effects ([@B18]). Evidence suggesting bacteria contribute to approximately 70% of fecal and 15% of serum metabolites highlights the importance of understanding metabolite origin ([@B78]). An *in silico* approach including annotating metabolite data to host, diet or bacterial derived origins would contribute to this understanding ([@B64]). Proving the origin of a metabolite can be achieved *in vitro* and *in vivo* by a dual isotope/radio labeling of novel prebiotics to build databases for annotating and mapping metabolic networks through elucidating the pharmacokinetics of the prebiotics and the mechanism and site of action of the metabolites ([@B11]).

For those pursuing prebiotic research, this multi-dimensional approach should uncover how these compounds function within the diverse gut microbiome or at other sites.

Discussion on Untangling the *In Vivo* Effects of Probiotics and Prebiotics {#S3}
===========================================================================

Translating Effects of Probiotics and Prebiotics Into Real-Life Outcomes {#S3.SS1}
------------------------------------------------------------------------

Two recent publications questioned the *in vivo* benefits and safety of probiotics ([@B53]; [@B68]), but failed to provide sufficient, substantiated evidence on actual harm or lack of efficacy. Sweeping generalizations on probiotics as a whole should be avoided by properly documenting the strains used, and emphasizing their strain-specificity and mechanisms of action ([@B36]; [@B62]). Probiotic strains with a safe history of use should be tested in small pilot trials in humans with detailed sampling and safety assessment, especially in high risk populations and regarding long-term effects ([@B34]; [@B62]). When strains pose a safety concern, postbiotics, or "bioactive compounds produced by food-grade micro-organisms during a fermentation process," might be an efficient alternative ([@B79]). Subsequently, large well-designed and properly controlled trials in the target host are needed to obtain evidence of benefit, optimal dose, and intended clinical uses ([@B62]).

Understanding the influence of interpersonal differences on clinical outcomes would greatly contribute to the efficacy of probiotic and prebiotic interventions ([@B46]; [@B58]). However, this is not a trivial task, and it is often not yet clear why a strain or compound is more effective in some individuals than others ([@B61]). Future research should focus on stratification of clinical trials based on individual characteristics of the participants, including sex, ethnicity, diet, and the functional characteristics of their microbiome. Already, the need for microbiome research to emphasize function rather than microbiota composition has been raised ([@B55]). This requires metabolomic tools and small molecule identification aligned with clinical evidence of cause and effect.

We advocate for adopting a systems approach that integrates readouts of functional microbial and health data in a range of samples (including stool, urine, blood, mucosa and saliva) from clinical trials. The readouts should focus on functional interactions with the host and how they are influenced by additional factors (e.g., drugs, pollutants, nutrients). This can be reasonably well achieved with a combination of *in silico, in vitro*, and *in vivo* approaches ([Table 1](#T1){ref-type="table"}). Precise metabolic modeling may predict which probiotic or prebiotic would be most likely to help an individual realize an effective personalized nutrition strategy for treating disease and promoting health ([@B70]). Response profiles to probiotic interventions can and should be evaluated in humans, even if it requires complicated tools like assessing the transcriptome. Such studies reveal that different probiotic *Lactobacillus/Lacticaseibacillus* strains induce different gene-regulatory pathways in the small intestinal mucosa of healthy volunteers ([@B73]).

Approaches like this provide avenues for understanding the individual-specific effects of different probiotic strains and facilitate their rationally designed clinical application. An exciting future goal would be to develop personalized probiotics and prebiotics. However, given there is no single healthy microbiome ([@B39]), the personalized concept may not require individual remedies, but rather sufficient options to manipulate functions shared by many.

Probiotics, Prebiotics and the Microbiome: An Ecological Perspective {#S3.SS2}
--------------------------------------------------------------------

When exploring probiotic and prebiotic effects at distant sites, it is critical to consider the complex microbial ecosystems of those niches. The administered probiotic should ideally promote homeostasis. Longitudinal and body niche-specific microbiome sampling ([@B22]) is important to assess the dynamic changes resulting from probiotic and prebiotic interventions. This is helped by non-invasive devices, such as an osmotic pill for real-time *in vivo* microbiome sampling of difficult to access niches in the gut ([@B48]) ([Table 1](#T1){ref-type="table"}). This pill is ingestible, biocompatible and does not require a battery. It has an integrated osmotic sampler and microfluidic channels, allowing for real-time sampling of the gut lumen and its microbiome without the need for colonoscopy. This will help us understand the microbiome's response to probiotic or prebiotic administration and pave the way for lab-on-a-pill devices.

The manner in which probiotic strains adjust to the conditions of the target site are largely unknown. Global gene expression profiling and studying isogenic mutants showed that exopolysaccharide production affects lactobacilli survival in the human ([@B41]) and murine ([@B37]) intestine. Interplay with environmental factors (e.g., medication, pollutants, nutrients) must also be investigated to truly appreciate factors that can influence probiotic strain activity and health of the host. Ultimately, an integrative approach would not simply establish dose-response relationships to treatment, but rather attempt to align what enters our system, how it is processed, and what microbes can be delivered to improve the net effect. It is thus inevitable that systematic approaches should be implemented to elucidate how an administered probiotic or prebiotic interacts with the host at various levels (e.g., the immune stimulator/modulator effect, microbiome, medication interactions).

The ecologic perspective will not be complete without identifying how changes in the relative abundance of one species impacts the relative abundances of others. Interdependency of sequencing data overlooks the real population dynamics. An ecosystem includes different interactions: co-operation, competition, exploitation, mutualism, co-dependency, commensalism, and amensalism, and these interactions can play a role in microbiome stability ([@B16]). Importantly, the microbiome datasets obtained with high throughput sequencing are compositional, as they consist of proportions with a constant sum, therefore compositionally appropriate tools should be applied for their analysis ([@B24]). To assess these complex interactions, evaluation of relative microbial community composition (e.g., by 16S rRNA gene or shotgun DNA sequencing) should be combined with species-specific qPCR for abundance, whole-transcriptome shotgun sequencing and proteomics to determine function ([@B52]) ([Table 1](#T1){ref-type="table"}). These approaches will allow to identify functional changes, adaptability and ecological interactions of probiotics and prebiotics with indigenous host microorganism communities. Large datasets generated using these multi "omics" could facilitate the hypothesis-driven studies at different levels of evidence.

Impact Beyond the Bench {#S3.SS3}
-----------------------

Probiotics, and to a lesser extent prebiotics, are now widely available to people in developed countries. Nevertheless, continual education is needed as too often the media or companies misrepresent what these are and what they can do ([@B55]). On a global front, people in developed and especially developing countries could benefit from probiotic products due to effects against infectious diseases, but the lack of affordable and well-documented strains is a hindrance ([@B31]). Various probiotic initiatives to better influence developing countries, including [Westernheadseast.ca](https://Westernheadseast.ca), [Yoba4Life.org](https://Yoba4Life.org), and Yogurito (Argentina), have proven that populations in low-income regions derive benefits beyond probiotic-mediated health, as seen by facilitating economic development and fighting malnutrition with local resources ([@B56], [@B57]). Every country should take action to implement programs allowing the poorest of their society access to fermented foods and probiotics that reduce the risk of key diseases: diabetes, malnutrition, infections.

We could also harness the power of beneficial microbes to ameliorate the impact of worldwide problems. A study showed that the probiotic *Lacticaseibacillus rhamnosus* GR-1 can sequester the heavy metals lead and cadmium, effectively reducing their translocation across the intestinal epithelium *in vitro* ([@B17]). Thus, administration of certain probiotic strains may offer a simple and effective option to reduce the amount of heavy metals absorbed from foods in contaminated regions of the world. Novel marine probiotics can also help prevent ecological damage, for example by increasing coral resistance to bleaching ([@B59]). When such applications become feasible, many opportunities will arise for early career researchers in the field of probiotics and prebiotics.

Concluding Remarks and Future Perspectives {#S4}
==========================================

Current technological and methodological developments offer exciting possibilities for probiotics and prebiotics research and applications. New tools allowing real-time studies in humans and following a microbe as it integrates into an existing microbiota, as well as systems that can quantify levels of health, will drive this field forward. Read-outs on what microbes are present, their interaction with the host and the influence of environmental factors (e.g., drugs, nutrients) will become standard when going for a physical examination in the future.

Novel sampling systems will elucidate how an applied probiotic or prebiotic interacts with the host at various levels, including the immune system, metabolism and all components of the microbiome. Ultimately, an integrative approach will support a form of personalized medicine to establish dose-response relationships for treatment, but moreso attempt to align what enters our system, how it is processed, and which probiotics or prebiotics deliver the best desired effects. Mechanistic insights into effector molecules will pave the way for emerging concepts, such as postbiotics.

As early career scientists, we want to be part of a society that uses beneficial microbes to help solve global problems, such as reducing the risk and impact of disease (including viruses and pandemics) and removing drugs and toxins from our food and environment. These will be exciting times with many career paths open for probiotics and prebiotics research in the sciences and applied to many other disciplines.
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